Von Hippel Lindau Disease With Multiorganic Localization in a Younger Male Patient – Case Raport and Short Literature Review

1. Coco D, Leanza S. Von Hippel-Lindau Syndrome: Medical Syndrome or Surgical Syndrome? A Surgical Perspective. J Kidney Cancer VHL. 2021 Dec 5;9(1):27-32. doi: 10.15586/jkcvhl.v9i1.206. PMID: 34963877; PMCID: PMC8652351 Search in Google Scholar

2. Larcher A, Belladelli F, Fallara G, Rowe I, Capitanio U, Marandino L, Raggi D, Capitanio JF, Bailo M, Lattanzio R, Barresi C, Calloni SF, Barbera M, Andreasi V, Guazzarotti G, Pipitone G, Carrera P, Necchi A, Mortini P, Bandello F, Falini A, Partelli S, Falconi M, De Cobelli F, Salonia A. Multidisciplinary management of patients diagnosed with von Hippel-Lindau disease: A practical review of the literature for clinicians. Asian J Urol. 2022 Oct;9(4):430-442. doi: 10.1016/j.ajur.2022.08.002. Epub 2022 Sep 10. PMID: 36381595; PMCID: PMC9643295.) Search in Google Scholar

3. Pradhan R, George N, Mandal K, Agarwal A, Gupta SK. Endocrine Manifestations of Von Hippel-Landau Disease. Indian J Endocrinol Metab. 2019 Jan-Feb;23(1):159-164. doi: 10.4103/ijem.IJEM_252_18. PMID: 31016171; PMCID: PMC6446673 Search in Google Scholar

4. van Leeuwaarde RS, Ahmad S, van Nesselrooij B, et al.Von Hippel-Lindau Syndrome. 2000 May 17 (Updated 2023 Sep 21). In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® (Internet). Seattle (WA): University of Washington, Seattle; 1993-2023 Search in Google Scholar

5. Karimi S, Arabi A, Shahraki T, Safi S. Von Hippel-Lindau Disease and the Eye. J Ophthalmic Vis Res. 2020 Feb 2;15(1):78-94. doi: 10.18502/jovr.v15i1.5950. PMID: 32095212; PMCID: PMC7001024. Search in Google Scholar

6. Hudler P, Urbancic M. The Role of VHL in the Development of von Hippel-Lindau Disease and Erythrocytosis. Genes (Basel). 2022 Feb 17;13(2):362. doi: 10.3390/genes13020362. PMID: 35205407; PMCID: PMC8871608. Search in Google Scholar

7. Waldum H. Dysfunction of von-Hippel Lindau factor causes reduced degradation of HIF leading to renal cancer. Hypoxiainducible factor-prolyl hydroxylase enzyme inhibitors also lessen HIF destruction and could therefore increase renal cancer. Front Pharmacol. 2023 Jun 6;14:1170796. doi: 10.3389/fphar.2023.1170796. PMID: 37346300; PMCID: PMC10279847. Search in Google Scholar